The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection von Gay, C., Kuruc, J.D., Falcinelli, S.D., Warren, J., Kirchherr, J.L., Sholtis, K., Allard, B., Stuelke, E., Gamble, A., Plachco, A., Tcherapanova, I., Eron, J.J., Goonetilleke, N., DeBenedette, M., Nicolette, C.A., Archin, N.M., Margolis, D.M.

Volltext

Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection... von Margolis, D.M, James, K.S, Tuyishime, M, Falcinelli, S.D, Joseph, S.B, Allard, B, Kirchherr, J.L, Clohosey, M, Gorelick, R.J, Gama, L, Koup, R.A, Mascola, J.R, Floris-Moore, M, Ferrari, G, Eron, J.J, Kuruc, J.D, Archin, N.M, Gay, C.L

Volltext